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Clinical Record
Hearing loss and fluctuating hearing levels in X-linked
hypophosphataemic osteomalacia
G PANTEL*†, R PROBST†, M PODVINEC*, N GU¨RTLER*†
Abstract
Background and objective: X-linked hypophosphataemic osteomalacia is the most common of the genetically
determined forms of osteomalacia. The occurrence of hearing loss in X-linked hypophosphataemic
osteomalacia has been known since 1984. However, observations on the progression of such hearing loss, and
suggestions regarding possible therapy, have not previously been published.
Methods: Case report of a patient with X-linked hypophosphataemic osteomalacia and hearing loss, with
three years’ audiological follow up, description of empirical therapy and literature review.
Results: The patient presented with fluctuating hearing. An audiogram showed mild to severe sensorineural
hearing loss mainly in the low and high frequencies. A temporary improvement of 20–40 dB after steroid
therapy was observed. Four weeks later, hearing had deteriorated again, mainly in the low frequencies. After
one year of fluctuating hearing levels, stabilisation occurred.
Conclusions: In X-linked hypophosphataemic osteomalacia, hearing loss occurs predominantly in the low and
high frequencies. The hearing loss type and progression pattern point to an endolymphatic hydrops as the
pathogenetic mechanism. Steroid therapy may be of some benefit.
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Introduction
X-linked hypophosphataemic osteomalacia (OMIMþ
307800) (¼Online Mendelian Inheritance in ManTM,
http://www.ncbi.nlm.nih.gov) is the most common of the
genetically determined forms of osteomalacia. It is charac-
terised by reduced tubular reabsorption of phosphate, and
is most frequently inherited as an X-linked dominant trait.
Other forms, such as an autosomal dominant variant, are
very rare.
Hypophosphataemia persists throughout life and may be
the only symptom. In childhood, bone deformities and
growth retardation are also common.1,2 In older patients,
extraskeletal bone formation occurs in ligaments and
tendons.3 In 1995, X-linked hypophosphataemic osteoma-
lacia was discovered to be caused by mutations in the
PHEX gene, which is involved in protein degradation.4
The association between X-linked hypophosphatae-
mic osteomalacia and hearing loss was first reported
in 1984.1 Twenty-five patients from 16 families were
studied. Nineteen patients (76 per cent) had a hearing
impairment of greater than 15 dB. Sixteen patients
were considered to have sensorineural hearing loss and
three to have mixed conductive–sensorineural hearing
loss. The hearing loss affected exclusively the high fre-
quency range in five patients and both the high and
low frequencies in 14. The results of caloric testing
showed reduced vestibular function in about 50 per
cent of patients.
Meister et al. reported a similar study on 19 patients.5
They found a measurable hearing loss in three out of 19
patients (16 per cent). All three showed a mild, bilateral
sensorineural hearing loss, affecting the high frequencies
in two cases and the low frequencies in one.
Both studies concluded that the origin of the hearing loss
in X-linked hypophosphataemic osteomalacia was at the
level of the cochlea, according to the results of audiometric
evaluation, which included measurement of otoacoustic
emissions and auditory evoked potentials. The pathological
mechanism leading to cochlear hearing loss remains
unclear. On the basis of osteosclerosis of the petrous
bone, seen on radiographic imaging, it was postulated
that such cochlear hearing loss was caused by structural
changes, which either alter the metabolism of the stria vas-
cularis, or compress the endolymphatic sac or duct and thus
produce an endolymphatic hydrops.1,3
We present the case of a patient suffering from X-linked
hypophosphataemic osteomalacia and hearing loss. For the
first time, audiological follow up over a three-year period is
reported, as well as the outcome of steroid therapy.
Case report
History
A 55-year-old man presented in December 2003 complain-
ing of fluctuating hearing on the left side, with deterio-
ration on the right side one month later. He also
described loud tinnitus occurring periodically on both
sides. Dizziness, otalgia and otorrhoea were not reported.
The patient had been known to suffer from X-linked
hypophosphataemic osteomalacia since birth. Apart from
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hearing loss, he did not have any other complaints, and was
taking no medication related to X-linked hypophosphatae-
mic osteomalacia.
Laboratoryexaminations revealed a slightly raised alkaline
phosphatase concentration (165 U/l; normal range 122
U/l), and no indications of infection.
Initial otological and audiometric findings
The external auditory meatus, the tympanic membrane and
the tuning fork tests were normal. Pure tone audiography
showed a symmetrical, moderate to severe, sensorineural
hearing loss predominantly in the low and high frequency
range (Figure 1). The tympanogram and the stapedius
reflex thresholds were normal. Auditory evoked potential
audiometry showed a clear V wave within normal latencies.
Wave I was not identifiable, indicating a cochlear rather
than retrocochlear pathology. The patient refused vestibu-
lar examination.
Radiology
A narrowing of the internal auditory meatus and modest
sclerosis of the petrous bone were seen on high resolution
computed tomography (CT) scanning (Figure 2). Vascular
pathology and an intracranial mass were ruled out by mag-
netic resonance imaging (MRI) with MR angiography.
Progression
The patient was initially commenced on a decreasing dosage
of prednisone (initially 60 mg per day for four days, decreas-
ing by 10 mg every second day for 14 days in total). On com-
pletion of this therapy, the patient’s hearing threshold levels
showed a marked improvement of 20–40 dB HL in the low
and middle frequencies (Figure 3), although mainly on the
left side. Otoacoustic emissions, measured at the same time
as the audiogram shown in Figure 3, were not detectable.
This improvement lasted for four weeks. No change of
tinnitus was reported.
Over the next six months, fluctuation of hearing
threshold level and tinnitus was observed, with
deterioration of hearing in the low and middle frequency
ranges (Figure 4). A maintenance dose of steroids was pro-
posed to the patient but refused.
The hearing threshold level stabilised spontaneously
one year after the onset of symptoms. At this time, pure
tone audiography showed a mild to moderate hearing
loss with markedly improved hearing in the low and
middle frequency ranges of the left ear. The hearing
threshold level of the right ear remained almost unchanged
(Figure 5).
A sudden hearing loss in both ears occurred almost two
years after the onset of symptoms. Unfortunately, the
patient did not present immediately, so no audiogram was
performed at that time. At the consultation four weeks
later, hearing in the left ear had completely recovered,
while hearing in the right ear remained decreased by about
10–15 dB (Figure 6). Repeated treatment with steroids was
refused by the patient. Over the whole follow-up period, no
medication for X-linked hypophosphataemic osteomalacia
was administered. Disease markers and clinical examination
did not show any progression of X-linked hypophosphatae-
mic osteomalacia in the patient.
Discussion
The literature describing X-linked hypophosphataemic
osteomalacia and hearing loss is scarce and outdated. In par-
ticular, progression of hearing impairment and possible
therapeutic strategies are not described. The audiological
phenotype of patients with X-linked hypophosphataemic
osteomalacia varies widely. Hearing is affected mainly in
the high frequencies in about 45 per cent, in the low frequen-
cies in about 5 per cent and in both frequency ranges in 50
per cent. Hearing loss has been consistently attributed to a
cochlear source. The degree of hearing loss ranges from
mild to severe.1,5 Our patient suffered from a mild to mod-
erate sensorineural hearing loss mainly in the low and high
frequency ranges. Auditory evoked potentials did not
show any neuroconduction impairment. All these obser-
vations are in accordance with the literature.
Our patient’s substantial improvement after initial steroid
therapy was asymmetrical, limited to the low andmiddle fre-
quencies, and only lasted for four weeks. Of course, the
possibility of a spontaneous recovery unrelated to therapy
cannot be excluded. Over the following months, the extent
of the hearing threshold fluctuation corresponded to the
improvement achieved by therapy. However, in contrast,
the patient’s hearing remained stable in the first four
weeks after completion of therapy. After one year, a spon-
taneous and lasting stabilisation occurred in the left ear.
The previously documented low frequency hearing loss
recovered. In summary, over the observation period, pro-
gression of hearing loss was characterised by fluctuations.
While some recovery was seen on one side, the other side
stabilised at a mild to severe level of hearing loss.
Our patient’s fluctuating hearing, mainly affecting the
low frequencies, supports the hypothesis of an underlying
endolymphatic hydrops as the cause of hearing impair-
ment. Davies et al. performed electrocochleography in
two patients and demonstrated an endolymphatic
hydrops.1 This examination was refused by our patient.
The progression and audiometric results of our patient
are comparable to MMenie`re, although he has never com-
plained of vertigo.
The alternative theory, postulating neural compression
or narrowing of the endolymphatic sac, seems rather unli-
kely. While Davies et al. described a normal internal audi-
tory meatus,1 O’Malley et al. reported generalised
osteosclerosis and narrowing of the internal auditory
meatus.3 Still, both groups postulated that hearing loss
FIG. 1
Pure tone audiogram on first consultation, showing
symmetrical, bilateral, moderate to severe hearing loss in the
low and high frequency ranges. Bone conduction: o ¼ right,
x ¼ left; air conduction: .¼ right, ,¼ left.
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was of cochlear origin, based on their audiometric
results.1,3 Our patient’s CT scans showed mild osteosclero-
sis of the petrous bone and some narrowing of the internal
auditory meatus, thus refuting the compression theory.
In addition, cerebral MRI and auditory evoked potentials
did not indicate any retrocochlear lesion.
. X-linked hypophosphataemic osteomalacia is the
most common of the genetically determined forms
of osteomalacia
. Hearing loss in this condition is characterised by
repeated episodes of sudden decrease,
predominantly in the low and high frequencies
. While hearing may recover, a stabilisation occurs at
around 60 dB HL after a few years. Steroids may
have some therapeutic benefit
The therapy used for our patient also supports
the theory of an endolymphatic hydrops as the underlying
pathogenetic mechanism of hearing loss in X-linked hypo-
phosphataemic osteomalacia. Prednisone is used in the
therapy of various cochleo-vestibular diseases, utilising
various mechanisms,6 such as anti-inflammatory and
mineralocorticoid receptor mediated effects, especially
in the stria vascularis. In addition, glucocorticoids are
involved in the homeostasis of the inner-ear fluids by
regulation of aquaporines, membrane channels respon-
sible for water transport.6
An additional line of evidence for the proposed pathoge-
netic mechanism and beneficial effect of steroids stems
from molecular genetic studies. Most studies on the
mouse model of X-linked hypophosphataemic osteomala-
cia indicate that the renal dysfunction observed is the
result of a circulating factor rather than a genetic renal
defect.7 Bearing this in mind, the assumed circulating
factor causing X-linked hypophosphataemic osteomalacia
FIG. 2
High resolution, axial computed tomography scan of the petrous bone, showing narrowing of the internal auditory meatus (arrows)
and modest sclerosis of the petrous bone.
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may precipitate in the stria vascularis, thereby disturbing
the metabolism of the stria vascularis, either by local
inflammatory changes or as a result of the precipitate
itself. This hypothesis is further supported by the other
mouse model (Gy phenotype), in which histological exam-
ination points to a degenerative process in the cochlea.8,9
The histological finding of degenerate hair cells corre-
sponds to the absent otoacoustic emissions seen in our
patient. Steroids would have a positive impact on local
inflammatory changes as well as on the disturbance of
homeostasis. These two beneficial effects resulted in
steroids being the first choice of therapy for our patient,
compared with other possible treatments for endolympatic
hydrops, such as diuretics.
The treatment of X-linked hypophosphataemic osteoma-
lacia incorporates calcitriol and phosphate salts. However, in
our patient’s case, use of such agents was precluded by their
serious side effects, such as nephrocalcinosis and hyperpar-
athyroidism, and the fact that they have not previously
been administered in patients with X-linked hypophospha-
taemic osteomalacia and hearing loss.1,3
FIG. 4
Pure tone audiogram after six months, showing further hearing
deterioration in the middle frequencies. Bone conduction: o ¼
right, x ¼ left; air conduction: .¼ right, ,¼ left.
FIG. 6
Pure tone audiogram after 24 months, showing an almost
unchanged hearing threshold level in the left ear and a
decrease in the right ear of 10–15 dB HL. Bone conduction:
o ¼ right, x ¼ left; air conduction: .¼ right, ,¼ left.
FIG. 3
Pure tone audiogram after completion of initial steroid
therapy, showing improved hearing threshold mainly in the
low frequencies. Bone conduction: o ¼ right, x ¼ left; air
conduction: .¼ right, ,¼ left.
FIG. 5
Pure tone audiogram after 18 months, showing mild to
moderate hearing loss with markedly improved hearing in
the low and middle frequency ranges of the left ear. The
hearing threshold level in the right ear has remained almost
unchanged. Bone conduction: o ¼ right, x ¼ left; air
conduction: .¼ right, ,¼ left.
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Conclusions
Hearing loss in X-linked hypophosphataemic osteomalacia
is characterised by repeated episodes of sudden decrease,
predominantly in the low and high frequencies. While
hearing loss may recover, stabilisation occurs at around
60 dB HL after a few years. Steroids may have some thera-
peutic benefit.
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